EU-India trade deal could derail generic supply chain, MSF warns
This article was originally published in Scrip
Médecins Sans Frontières (MSF) has warned that the stringent intellectual property enforcement and injunction measures in the proposed EU-India free trade agreement (FTA) could have "chilling" implications for the entire generic medicine supply chain. The international NGO says that the free trade agreement as drafted imposes another piece of legislation, the Anti-Counterfeiting Trade Agreement (ACTA), implementation of which would threaten a range of programmes including those funded by the US President's Emergency Plan for AIDS Relief, UNITAID and the Global Fund, and hurting active pharmaceutical ingredients suppliers from India and possibly China.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.